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Editorial Comment 
No Reflow Revisited* 
ROBERT A. KLONER, MD, PHD 
Los Angeles, California 
The no reflow phenomenon. This term refers to the inabil- 
ity to reperfuse myocardial tissue after removal of a coro- 
nary artery occlusion (1). This phenomenon occurs not only 
in cardiac tissue subjected to ischemia plus reperfusion, but 
also in brain, skin and kidney (1). 
Initial descriptions (1,2) of the no reflow phenomenon in 
the heart were obtained using experimental preparations in 
which a coronary artery was occluded for various periods of 
time; the coronary occlusion was then removed and the 
vasculature injected with dye. In our initial study (1) anes- 
thetized dogs were subjected to either 40 or 90 min of 
ischemia followed by reperfusion. Thioflavin S (a fluorescent 
stain specific for endothelial cells) or carbon black was 
injected intravenously after 10 to 12 s and 5 or 20 min after 
removal of the coronary clamp. After a 40 min period of 
ischemia followed by reflow, the tracers were distributed 
homogeneously throughout the myocardium. However, af- 
ter 90 min of ischemia, portions of the subendocardium were 
not penetrated by these dyes after 10 to 12 s and 5 or 20 min 
of reflow. In a later study (3) we observed perfusion defects 
in the subendocardium and portions of the mid-myocardium 
when thioflavin S dye was injected after 3 h of occlusion and 
3 h of reperfusion. Furthermore, the anatomic distribution of 
no reflow, determined by dye injection, also correlated with 
a reduction in regional myocardial blood flow as determined 
by radioactive microspheres (3). In both of these studies the 
zones of no reflow were confined to areas where the myo- 
cardial cells were already dead (as determined by either 
electron microscopy or tetrazolium staining). Therefore, we 
thought it unlikely that no reflow was playing a major role in 
causing myocardial cell death. 
A recent study (4) suggests that the no reflow phenome- 
non may become worse over time. Using a 90 min period of 
transient coronary occlusion, Ambrosio et al. (4) observed 
that the area of impaired perfusion assessed by thioflavin S 
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increased in size nearly threefold between 2 min and 3.5 h 
after reperfusion. Postmortem injection of silicone rubber 
showed that areas devoid of capillary filling also increased 
between 2 min to 3.5 h after reperfusion. Whether this 
progressive reduction in flow after reperfusion contributes to 
irreversible myocardial cell damage is unknown. 
Mechanisms of no reflow. There have been a host of 
mechanisms proposed to explain the no reflow phenomenon. 
In our 1974 study (1) electron microscopic evaluation of no 
reflow areas was obtained to learn more about the mecha- 
nisms of no reflow. The most striking feature was damage to 
the microvasculature, including decreased endothelial pi- 
nocytotic vesicles, endothelial gaps, endothelial protrusions 
or blebs (which often appeared to be occluding the capillar- 
ies), fibrin tactoids and rouleaux formation of erythrocytes. 
On rare occasions swollen myocytes were observed, which 
appeared to be compressing the capillaries. We doubt that 
the fibrin tactoids are a major contributor to no reflow 
because neither streptokinase nor tissue plasminogen acti- 
vator prevented this phenomenon in a mechanical model of 
coronary occlusion plus reperfusion (3,5). 
Whereas it appears certain that no reflow is due at least in 
part to microvascular injury, the factors responsible for 
endothelial cell damage after ischemia and reperfusion are 
uncertain. In anesthetized dogs subjected to 2 h of transient 
coronary artery occlusion, we recently observed (6) that no 
reflow was significantly attenuated by administration of the 
potent free radical scavenging agents superoxide dismutase 
and catalase at the time of reperfusion. Furthermore, the 
enhanced blood flow after reperfusion in dogs treated with 
these two agents in combination was accompanied by 
marked preservation of the vascular endothelium (6). These 
data suggest that no reflow may be a consequence of free 
radical-mediated microvascular damage. 
Accumulation of activated neutrophils in previously 
ischemic myocardium may contribute to no reglow, both by 
acting as a source of oxygen radicals (6) and by physically 
occluding or “plugging” the microvessels (4,5,7). It is clear, 
however, that neutrophils are not absolutely necessary to 
induce no reflow. For example, no reflow occurs in isolated 
perfused heart preparations devoid of neutrophils Q-10). In 
addition, we (1) observed areas of no reflow within 10 to 12 s 
of removal of the coronary clamp, which may be too short a 
time for neutrophils to migrate into the previously ischemic 
myocardium. Although neutrophils may not mediate acute 
no reflow, their subsequent migration into the previously 
ischemic tissue may account for the later worsening of no 
reflow as described by Ambrosio et al. (4). 
The present study. In the study of Carlson et al. (11) in 
this issue of the Journal, anesthetized dogs were subjected to 
2 h of coronary occlusion followed by 4 h of reperfusion. 
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Bovine neutrophil antiserum was utilized to reduce circulat- 
ing neutrophil counts by an average of 81%. This reduction 
in neutrophils did not modify no reflow assessed with the 
radioactive microsphere technique. Their data thus support 
the concept that neutrophils are not important in the patho- 
physiology of no reflow. However, as the authors point out, 
suppression of neutrophils with antiserum was not complete: 
the data of Engler et al. (7) suggest that only very few 
neutrophils may be needed to cause microvascular plugging. 
Furthermore, the total number of neutrophils within the 
myocardium may be less important than their state of 
activation. It is conceivable that had leukopack filters been 
used to more completely remove neutrophils from the reper- 
fusate, no reflow might have been blunted. Nevertheless, the 
data of Carlson et al. (11) do support the notion that other 
factors besides neutrophils contribute to no reflow. 
Clinical implications. What are the clinical implications 
of the no reflow phenomenon? “No reflow” has now been 
described in patients after thrombolysis (12). It is our opin- 
ion that no reflow is a secondary phenomenon that occurs 
because of microvascular injury within areas of dead myo- 
cardial cells. There has been no convincing evidence that 
reduction of the no reflow phenomenon will limit the extent 
of myocyte injury. Thus, in the clinical setting, therapy 
aimed primarily at reducing no reflow is unlikely to reduce 
infarct size. However, reducing the no reflow phenomenon 
could conceivably result in certain beneficial effects indepen- 
dent of infarct size reduction. For example, maintaining 
perfusion into areas of infarcted myocardium could facilitate 
the removal of necrotic debris and theoretically hasten the 
healing process. In this regard, it has been shown in exper- 
imental studies (13-16) that late coronary reperfusion (too 
late to reduce myocardial infarct size) may increase scar 
thickness, reduce myocardial infarct expansion and reduce 
the severity of ventricular arrhythmias. In addition, main- 
taining blood flow through necrotic tissue may provide a 
route by which drugs can gain access to adjacent zones of 
reversibly injured myocardium. 
Conclusions. The no reflow phenomenon is a well recog- 
nized consequence of reperfusion after ischemia. It is un- 
likely that it contributes primarily to irreversible myocardial 
cell death. No reflow is most likely due to microvascular 
damage, perhaps mediated by oxygen free radicals. Throm- 
bolytic agents do not prevent no reflow, suggesting that 
fibrin deposition is not a major mechanism. Whereas neutro- 
phi1 plugs also have been suggested as a possible cause for 
no reflow, the present study by Carlson et al. (I 1) suggests 
that other factors contribute. 
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